Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab Plus Azacitidine in Newly Diagnosed AML
NCT04023526Phase 2Active, not recruiting
- Sponsor
- OncoVerity
- Start
- Jul 2019
- Primary completion
- Aug 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised trial of cusatuzumab in acute myeloid leukemia (AML) (2 arms), sponsored by OncoVerity. Primary endpoint: Complete Remission. Started Jul 2019; status: active, not recruiting.
02
Drugs
cusatuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04023526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023526.